Try our Advanced Search for more refined results
Life Sciences - January, 2016
339 articles
- 5 Firms To Guide 1st Wave Of 2016 IPOs Led By Biotechs
- Shkreli Defeat Points To Complicity Of Kaye Scholer Atty
- PTAB To Review Cubicin Patents Challenged By Fresenius
- KaloBios Trustee Protests Hiring Of Morris Nichols
- 4th Circ. Says FCA Bars Suit Based On Lawyer's Knowledge
- Indivior Fights For Sales Docs In Product-Hopping Case
- Fed. Circ. Backs PTAB's Nixing Of Illumina DNA Patent Claims
- Becton Shakes Hospital's Antitrust Suit Over Syringes
- 31 Accutane Suits Tossed After Docs Would Prescribe It Again
- The FDA's Priority List For 2016
- Expectation Damages Now A Real Possibility In Delaware
- Ala. Pharmacists To Admit Guilt In Fatal Compounding Case
- Pa. Court Urged To Extend Time Bar For Risperdal Suits
- SIGA Shareholder Blasts Ch. 11 Plan Over Creditor Treatment
- Wright Medical Says $11M Hip Implant Verdict Has To Go
- Mass. Drugmaker Sued After Antibiotic Fails, Shares Tank
- Drug Provider Tells 7th Circ. W.Va. 'Pill Mill' Suit Is Covered
- AAI Warns FTC Of Impact Of Teva's $40.5B Generics Deal
- Spectrum, Investors Get Preliminary OK Of $7M Settlement
- AIA Petition In Generic Zomig Case Is Time-Barred, PTAB Says
- The Precision Medicine Initiative's 1st Annual Checkup
- Cicero On Legal Advocacy
- CVS Escapes Vitamin E False Labeling Suit
- Real Estate Rumors: Hardesty & Hanover, Whole Foods, Sanofi
- ITC Seeks Full Fed Circ. Review Of Data-Blocking Authority
- Shkreli Emails To Kaye Scholer Atty Not Privileged: Judge
- WARF Wins Kidney Disease Treatment Royalty Battle
- Theranos Posed 'Immediate Jeopardy' To Patients, Feds Say
- Sen. Vows Filibuster Of FDA Nominee Over Big Pharma Ties
- Jones Day Snags Trio Of IP Attys From MoFo, Ropes & Gray
- Eli Lilly Says Canada Skewing Facts In $354M IP Arbitration
- KaloBios Says Proposed Bonuses Won't Go To Shkreli
- Thompson Hine Adds 2 Business Litigation Vets In NY
- Baxter Keeps Trade Secret Claims In HQ Arrhythmia Drug Suit
- Surgery Center Can Shield Some Info In Meningitis MDL
- Transportation Finance Lawyer Goes To King & Spalding
- Pa. Appeals Court Urged To Toss $3M Topamax Verdict
- Mass. AG Targets Gilead Over Hep C Drug Prices
- Shire Expert Opinions Draw Fire In Adderall Antitrust Suit
- 9th Circ. Raises The Bar For Crime-Fraud Exception
- 4 Ways To Improve The Business Intake Process
- 10 Global Challenges For Life Sciences Cos. In 2016
- Supplement Maker Calls Insurer's Challenges Premature
- Boston Scientific Counterfeit Mesh Material Row Sent To FDA
- Supreme Court Again Clarifies Standards For ERISA Claims
- Gilead Hit With Suit In HIV Drug Patent Manipulation Row
- Otsuka Sues Orchid Pharma to Halt Generic Abilify
- SEC Hits Penny Stock Trader For Registration Violations
- Medical Device Co. Tactile Systems Files For $86M IPO
- Vorys Adds IP Partner From Floundering Novak Druce
- Jury Deadlocks In Tylenol Death Retrial Against J&J Unit
- Nelson Mullins Adds Ex-Hollingsworth Pharma Pro
- FDA Warning Wire: Chernobyl, Rogue Rice, Device Lapses
- 3rd Circ. Stays Provigil Pay-For-Delay Trial During Cert. Appeal
- Sanders Places Hold On FDA Nominee Over Big Pharma Ties
- Merck Hit With Patent Suit Over Cancer Drug Keytruda
- Feds Say SEC Suit Should Wait For Shkreli's Criminal Case
- Mass. Hospital Operator Seeks To Duck Rival's Monopoly Suit
- Lawmakers, Cos. Back Fed. Circ. Enhanced Damages Test
- Greatbatch Wins $37.5M In AVX Patent Trial
- Examining Recent Corporate Integrity Agreement Trends
- Justices' Amgen Order Cements High Bar For ERISA Suits
- J&J Unit Owes $20M For Child's Tylenol Death, Jury Told
- NJ Mayor Jumps From Wilentz Goldman To Locks Law Firm
- Jury Awards Thermometer Co. $14.6M In Patent Fight
- 5th Circ. Grants Jailed ArthroCare Executives New Trial
- Lialda Patent Dispute Seeks Definition In Second Trial
- Sen. Holds Up FDA Nominee, Wants Fix For Opioid Approvals
- Morrison Cohen Nabs Venable Deals Pro To Grow Corp. Team
- Millennium Sues Wockhardt Over Generic Cancer Drug
- $37.5M Greatbatch-AVX Patent Fight Goes To Jury
- Editas Joins Biotechs Braving Sluggish IPO Market
- Baxter Must Give Brokerage Firm Docs To German Insurer
- FTC Probing Turing For Antitrust Violations, Shkreli Says
- 23andMe Says Exemption Doesn't Apply In DNA Test Actions
- 2nd J&J Pelvic Mesh Trial Kicks Off In Philly
- Investor Says HeartWare Lied About FDA Compliance
- Barnes & Thornburg Adds 2 Pharma IP Pros To Minn. Office
- High Court Sends Amgen ERISA Suit Back To 9th Circ. Again
- Merger Investigations Set Records In 2015
- St. Jude Hit With Class I Recall By FDA Over Faulty Devices
- Drug Buyers Must Play Nice At Trial, Provigil Judge Says
- J&J Can't Dodge Levaquin Side-Effect Suit For Tardy Filing
- Baxter Gets OK On $42.5M Deal In Securities Fraud Suit
- Judge Won't Toss Birth Defect Claims In Zofran MDL
- GSK Asks 3rd Circ. For Atty Fees For Late Thalidomide Suit
- Judge Threatens 'Severe' Sanctions In Xyrem IP Fight
- Taxation With Representation: Cravath, Skadden, Locke Lord
- 3 Traits Of Best-In-Class General Counsel
- Fed. Circ. Denies Longer Patent Term For Pfizer Cancer Drug
- Info Still Privileged If Atty Worked As Chemist, Idenix Says
- Pharma Co.'s Arbitration Bid Denied In $6M Contract Row
- UK Pharma Firm Concealed Poor Controls, Suit Claims
- Who's To Blame For 'Superbug' Outbreak And What's Next
- Acadia Shareholder's Suit Ends In $15.75M Deal
- Attorneys Not Giving Up On IPO Work Despite Jitters
- Shkreli, Lawmakers Spar Over Drug Price Testimony
- Acorda Strikes Patent Deal To Delay Par's Generic Ampyra
- Johnson Matthey Escapes Shire's Vyvanse Patent Suit
- Stem Cell Letter Could Signal New FDA Enforcement Trend
- 'Old School' Tools May Hinder Attorney Collaboration
- Solicitor General Wants In On High Court Patent Damages Row
- Hagens Berman Asks 3rd Circ. To Allow Thalidomide Suit
- AIPLA Urges Fed. Circ. To Update On-Sale Bar Rules
- Stem Cell Co. Hit With Class Action Over Board Rules
- Abingworth Raises $105M For Life Sciences Co-Development
- Calif. Mom Says Ill. Case Keeps Her J&J False Ad Suit Alive
- Apotex Exits Forest's Patent Suit Over Generic Savella
- Baxalta Investor Seeks To Halt $32B Shire Deal
- Allergan Loses IP Suit Accusing Venture Fund Of Extortion
- Privacy May Trump Free Speech In Anti-Abortion Video Suit
- NC Jury Sees Willful Infringement Of X-Ray Patent
- Del. Justices Ax Suit Over Failed AbbVie-Shire Merger
- Shkreli Called Before Congress To Talk Drug Price Hike
- GSK Scientists Charged With Plot To Sell Secrets In China
- Paul Weiss, Kirkland, Munger Vets Launch Trial Boutique
- Hogan Lovells Boosts IP Team With Duo From King & Spalding
- J&J Unit's Expert Slams Tylenol Death Timeline At Retrial
- Consumers Fight For Class Certification In Adderall Suit
- Hogan Nabs Prominent Trial Lawyer From FaegreBD
- 6 Types Of Legal 'Mumbo-Jumbo' Attorneys Must Avoid
- FDA Chides Hospira Over 'Misleading' YouTube Ad
- Deals Rumor Mill: Ashland, Banco Popular, BNP Paribas
- Fed. Circ. Affirms PTAB Ruling Axing Glucose-Testing Patent
- Gilead Says Idenix Can't Hide Docs Behind Atty-Chemist
- Manufacturer Holding Generic Lexapro 'Hostage,' Suit Claims
- FTC, Maine Accuse Weight Loss Cos. Of Marketing Scam
- DEA Says Wis. Tribe Can't Sue To Grow Hemp
- How Analytics Can Inform Early Strategy In Patent Cases
- GlaxoSmithKline Win Leaves Only One Avandia Injury Claim
- Cryolab Hosting Ted Williams' Remains Appeals Libel Suit
- Senate Panel Splits Approach To 21st Century Cures
- Cozen's Employment Co-Chairman Joins Drinker Biddle
- Supplement Buyer Class Based On Conjecture, Justices Told
- Express Scripts Tried To Shutter Small Pharmacies, Suit Says
- FDA Warning Wire: New Woes For Wockhardt
- High Court Nixes Boehringer's Appeal In FTC Doc Row
- High Court Refuses To Reinstate $15M Alps South Patent Win
- Justices Say Medtronic IP Suit Needs 2nd Look After Commil
- Lerner David Nabs Polsinelli Life Sciences & Patent Expert
- High Court Urged To Keep Fed. Circ. Enhanced Damages Test
- J&J Says Consumer In False Ad Suit Never Bought Product
- High Court Won't Hear J&J Appeal Of $140M Motrin Verdict
- 5 Insights From Sharp Electronics Deputy GC Deborah Tyler
- Indicted Pharma Exec Shkreli Dumps Arnold & Porter
- 1 Year Later, Teva Providing Less Certainty Than Expected
- Teva, Ex-Atty Settle Wrongful Firing Suit Prior To Trial
- Tylenol Victim Showed Signs Of Bacteria, Doctor Testifies
- New Del. Rule Not For OKing Future Actions, Judge Says
- Dow Can't Shake $456M Plant Patent Arbitration Loss
- Girardi Keese Urges Justices To Hear $10M Avandia Fee Fight
- MSCs In California Mass Tort Litigation: A Call For Reform
- Market Volatility Cools Attys' Hopes For 'JPMorgan Bounce'
- Fraud, Injunction Bids In Anti-Aging Products Suit Nixed
- KaloBios Creditors Ease Demands After Shkreli Pulls Back
- Ranbaxy Can't Split Antitrust Claims From Provigil Trial
- Ohio Sec. Of State Accused Of Holding Up Drug-Pricing Law
- Bayer Wins Dismissal Of 4 NJ Mirena Suits Filed Too Late
- FDA Details Cybersecurity Steps For Approved Med. Devices
- FDA Clears Redesigned Scopes In 'Superbug' Saga
- Ex-Va. Gov.'s Bribery Appeal Heads To Supreme Court
- Weak Trial Evidence Leads To Breg Pain Pump Suit Dismissal
- Deals Rumor Mill: Asahi Group, ChemChina, Sharp Corp.
- Track & Field Officials Accused Of Criminal Doping Plot
- Colo. Pot Credit Union Takes Key Account Suit To 10th Circ.
- Bard Loses Appeal Of $2M Pelvic Mesh Verdict At 4th Circ.
- Jazz's Xyrem Patent Cases Consolidated In NJ Fed Court
- Merck Pays $830M To End Investor Suit Over Vioxx Marketing
- Hospital Can't Revive 2 Meningitis MDL Bellwether Cases
- Boston Scientific Used Counterfeit Materials, RICO Suit Says
- PTAB Rejects Amgen's Bid For Humira Patent Reviews
- Fed. Circ. Vacates Re-Exam Ruling After Patent Expires
- Novartis, Actavis Settle Patent Infringement Suit
- Liberty Fights $3M Coverage For MusclePharm SEC Probe
- Deals Rumor Mill: Pfizer, EDF, Parques Reunidos
- Abilify User Says Drug Made Him Compulsively Gamble
- Sentence Reduced For MLB Doping Scandal Ringleader
- FDA's Post-Approval Drug Tracking Not Reliable, GAO Says
- No Need To Split Provigil Claims Before Trial, Cephalon Says
- Pharma Execs Banned From Leading Drug Cos. In Insider Case
- 5 Reasons High Court Should Not Take Bob McDonnell's Case
- In-NO-vation: Patentable Subject Matter In The Courts
- Tylenol Victim's Expert Concedes Killer Bacteria Not Found
- Jury Finds X-Ray Cos. Infringed Transformer Patent
- Gilead Can't Touch Attorney's Work In Merck Patent Suit
- J&J Moves Suit Over Children's Motrin Back To Federal Court
- PTAB Says It Wrongly Denied AIA Review In Pacemaker Case
- Report Says FDA, Device Makers Failed In Superbug Outbreak
- NJ Judge Stays Dr. Reddy's Purple Pill Suit Pending Appeal
- Eli Lilly Shakes Female Sales Reps' Bias Row At 3rd Circ.
- FedEx Says Most Illegal Drug Shipping Charges Outdated
- Fed. Circ. Says Same PTAB Panel Can Begin, End AIA Reviews
- Reckitt Benckiser Accuses Invoice Auditors Of Puffed-Up Fees
- Del. Justices Grill AbbVie Investors In Shire Docs Fight
- FTC Finds Major Drop In Possible Pay-For-Delay Deals
- On-Sale Bar Applies In Angiomax Dispute, Fed. Circ. Told
- Fed. Circ. Backs Pfizer's Patent For Cancer Drug Sutent
- Hyland's Faces 2nd Suit Over Homeopathic Baby Products
- Sidley Austin Nabs Veteran FDA Device Regulator
- Abbott Asks For Reconsideration To End Stent FCA Suit
- 2015's Most Complex Deals And The Firms That Led Them
- FTC Citing Bad Data In Telemarketing Fight, Lifewatch Says
- Congress' Conflicting Approach Toward Medical Marijuana
- Drug Licensees Subject To Federal Price Regulation In Canada
- BigLaw 2016: A Look Ahead
- KaloBios Judge Freezes $5.4M Over Investor Lawsuit
- J&J Unit Knew Fatal Tylenol Tainted, Jury Hears At Retrial
- Mirena Suit's Timeliness Hinges On NJ Ruling, Judge Told
- Takeda's Gout Drug IP Case Paused After Deal With Watson
- Tough PTAB Fight Ahead For Breakthrough Gene-Editing Tech
- Roquette Gets IP Arbitration Row Paused For Appeal
- Nixon Peabody OK'd As Adviser In Taylor-Wharton Ch. 11
- FDA Warning Wire: China Drugmaker Accused Of Data Deceit
- Ex-Agriculture Official Returns To Armstrong Teasdale
- Takeda Execs Admitted To Actos Scheme, Relator Claims
- Quest Diagnostics Hit With FLSA Wages Action
- Nasdaq Suspends KaloBios After Shkreli Arrest
- Reed Smith Atty's Widow, GSK Headed To Trial In Suicide Suit
- Top 10 Antitrust Developments And Trends To Watch This Year
- Fresenius Targets Post-Warning Claims In Dialysis Drug MDL
- FDA One Step Closer To New Chief After Senate Panel Vote
- Wyeth's 'Clear Evidence' Language: Clearly Misunderstood
- AVX And Greatbatch Face Off In Pacemaker Patent Trial
- Roquette Wants IP Arbitration Row Paused During Appeal
- Ill. Court Flips Insurer's Win In Chemical Mislabeling Suit
- NJ Doc's Patent Lawsuit Sunk By No-Sue Agreement
- Gerber Formula Buyers Near Cert. In Allergy False Ad Suit
- Aggrenox Judge Questions Need For Broad Market Discovery
- Apotex Doesn't Infringe Patent For Benicar, Judge Says
- How 5 Firms Forged Separate Paths To Shire, Baxalta Deal
- FDA Forbade Fosamax Warnings, Merck Tells 3rd Circ.
- Red-Hot Pharma Space Produces 2016's First Megadeal
- High Court Stays Out Of CAFA Dismissal Fight
- Orrick Gets 4-Atty IP Team From Struggling Kenyon & Kenyon
- Travelers Needn't Defend KFx In Patent Row, 9th Circ. Affirms
- Wachtell, Davis Polk Guide Thermo Fisher's Affymetrix Buy
- Judge Rips Plaintiffs' Attorney On Essure Pleadings
- Justices Turn Down Medtronic Infuse Preemption Appeal
- Chamber Details TPP Shortcomings On Patents, Data Flows
- High Court Won't Eye Risperdal Verdict Against J&J Unit
- Top FDA Developments Of 2015 And Predictions For 2016
- Inversions: Recent Developments And 2 Predictions
- Shire Inks $32B Deal For Baxalta
- Deal Makers Hope JPMorgan Conference Will Perk Up Biotechs
- Taylor-Wharton Defends Bid To Retain Nixon Peabody
- Life Sciences Group Of The Year: Wilson Sonsini
- Embezzling Ex-Pharma Manager In NJ Gets 5 Years
- P&G Asks Supreme Court To Nix Probiotic 'Snake Oil' Class
- Glenmark Tells Fed. Circ. Bayer Fell Short In Finacea IP Suit
- Bad Test Used For Pfizer Cancer Drug Patent, Fed. Circ. Told
- J&J Urges Appeals Court To Uphold Philly Risperdal Win
- Obama Vetoes Latest Attempt To Dismantle ACA
- Deals Rumor Mill: Time Warner, Simcere Pharma, Philips
- 3rd Circ. To Mull Tolling Standard In Merck Investor Row
- Charles River Laboratories Pays $585M For Drug Research Co.
- Consumers Again Lose Class Cert. Bid In Supple False Ad Suit
- 6 Steps To Becoming A Superior Supervising Attorney
- Fed. Circ. Upholds Invalidity Of Purdue's Sleep Aid Patents
- Top 10 Food And Drug Product Law Developments For 2015
- Get Ready For EU Unified Patent Court And Unitary Patent
- New FDA Guidance Advances Pharma Manufacturing Tech
- Shkreli Barred From Using E-Trade Funds Backing His Bond
- Bayer Says Women Haven't Proved Mirena IUD Caused Injuries
- Life Sciences Group Of The Year: Sidley Austin
- Sanofi Dodges Securities Fraud Class Action In NY
- Abbott, Whistleblower Can't End Stent False Claims Suit
- Deals Rumor Mill: Shire, Oi SA, The Linde Group
- House Passes Bill To Scrub 'Burdensome' Rules
- Judge Cold To Otsuka's Exclusivity Claims In FDA Row
- KaloBios Investors Sue Over Shkreli Arrest
- Intellectual Property Pro Joins Williams Mullen
- Allergan Expands Botox Hold With $90M Biopharma Co. Buy
- Toe Implant Fight Wrongly Sent To State Court, Stryker Says
- Post-Grant Challenges In Life Sciences: 2015 In Review
- 3rd Circ. Told Hangley Represented Nonexistent Co.
- Insurer Must Cover DNA Testing Co. In Privacy Suit
- Depomed, Endo Drop Patent Suit Over Painkiller Opana ER
- Australian Co. Takes Mylan Subsidiary Dispute To Singapore
- 3rd Circ. Won't Revive Ex-Pfizer Workers' Benefits Spat
- Life Sciences Group Of The Year: Irell & Manella LLP
- Apotex Loses Bid To Block Cephalon Experts In Provigil Trial
- House Sends ACA Repeal Bill To White House
- House Debates Bill To Eliminate 'Burdensome' Rules
- $227M In Bank, Biotech Filings Keep IPO Pipeline Gushing
- Hyland's False Ad Suit Always About Fake Drugs, Class Says
- Vitamin C Buyers Say Vodka TM Suit Can't Nix Antitrust Win
- SAC's $10M Class Action Settlement Gets Judge's Initial Nod
- Roche Leads Health Care Startup's $175M Fundraising Round
- NuVasive To Pay Up To $410M For Medical Tech Co. Ellipse
- GSK Faces Whistleblower Suit Claiming Study Mistakes
- Feds Fight Ex-Warner Chilcott Exec's Bid For Witness Info
- Families Say Animal Studies Back Their Claims In Zofran MDL
- LeClairRyan Adds IP Partner From Thompson Coburn
- Adderall Antitrust Class Shouldn't Win Cert., Shire Says
- Philly Risperdal Plaintiff Can't Get New Damages Trial
- Agilent To Pay Enzo $9M To End Patent Infringement Suit
- Colo. Pot Credit Union Loses Bid For Key Account
- Predictions For Anti-Corruption Enforcement This Year
- Life Sciences M&A Market Likely To Stay Hot In 2016
- FDA's Pelvic Mesh Scrutiny May Have Limited Impact In MDL
- Arrowhead Can't Ditch Investor Suit Over Hep B Drug Trial
- 6th Circ. Won't Rethink Orthofix Win In Trade Secrets Row
- Life Sciences Group Of The Year: Gibson Dunn
- Apotex Decries Biosimilar Notice Ruling At Fed. Circ.
- Law360's Pay-For-Delay Cheat Sheet For 2016
- 3rd Circ. Won't Revive Last Hagens Berman Thalidomide Suit
- Shippers Again Ask Judge To Nix AXA's $9M Drug Theft Row
- Generic-Drug Cos. Urge Senate To Fight FDA Approval Delays
- Nashville Pharmacy Co. Settles FCA Suit For Almost $8M
- Zoloft MDL Judge Keeps Focus On Pfizer's Bid To Toss Claims
- Deals Rumor Mill: Dell, Hansoh Pharma, Dalian Wanda
- FDA Warning Wire: Lawsuit Targets Defiant Compounder
- $10M Avandia Fee Fight Correctly Resolved, Justices Told
- 6 Health Cos. Line Up For IPOs In Busy 2016 Start
- Top 10 Health Law Developments In 2015 And What's Ahead
- FTC Can't See Certain Docs In AbbVie Pay-For-Delay Row
- FDA Rejected Warnings Sought In $140M Motrin Case: J&J
- Provigil Antitrust Trial Should Be Postponed, Drug Cos. Say
- Baxalta Inks $1.6B Cancer Drug Option Deal
- Engineering Contractor Leads 2016 Pipeline With $75M IPO
- AbbVie Ups Ante In Biosimilar Battle
- Endocyte Dodges Class Action Over Cancer Drug Claims
- Hagens Berman Blasted For 'Implausible' Claims In Lens MDL
- Deals Rumor Mill: Shire, New World Development, EQT
- Stryker Presses For More TIG Settlement Cash At 6th Circ.
- Profs Weigh In On 3rd Circ. Lipitor Pay-For-Delay Row
- Mylan 'Declared War' On AstraZeneca IP, Fed. Circ. Hears
- O'Melveny Hires Seasoned FDA Attorney For Its DC Office
- Novo Nordisk Hit With Bias, Whistleblower Suit In NJ
- FDA Raises Approval Barrier For Some Pelvic Mesh Devices
- Forced Registration Makes Flimsy Suit, Mylan Tells Fed. Circ.
- 5 Of The Top Drug And Device Developments In 2015
- Purdue Insomnia Patents Wrongly Put To Bed, Fed. Circ. Told
- Life Sciences Group Of The Year: Covington
- KaloBios Can Pay Workers, But Shkreli Barred Money
- Pathway Genomics To Pay $4M In FCA Settlement
- What Your Outside Counsel Doesn't Know About E-Discovery
- This Could Be A Monumental Year For The 340B Program
- What To Expect From State Attorneys General This Year